Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2019 | Oct. 31, 2019 | |
Document and Entity Information | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Sep. 30, 2019 | |
Entity File Number | 001-36182 | |
Entity Registrant Name | Xencor Inc | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 20-1622502 | |
Entity Address, Address Line One | 111 West Lemon Avenue | |
Entity Address, City or Town | Monrovia | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 91016 | |
City Area Code | 626 | |
Local Phone Number | 305-5900 | |
Title of 12(b) Security | Common Stock, par value $0.01 per share | |
Trading Symbol | XNCR | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 56,721,172 | |
Entity Central Index Key | 0001326732 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q3 |
Balance Sheets
Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 |
Current assets | ||
Cash and cash equivalents | $ 51,189 | $ 26,246 |
Marketable securities | 495,292 | 268,115 |
Accounts receivable | 4,349 | 10,187 |
Income tax receivable | 402 | 804 |
Contract asset | 15,000 | |
Prepaid expenses and other current assets | 7,533 | 10,375 |
Total current assets | 573,765 | 315,727 |
Property and equipment, net | 13,868 | 11,813 |
Patents, licenses, and other intangible assets, net | 14,027 | 11,969 |
Marketable securities - long term | 73,995 | 236,108 |
Income tax receivable | 402 | 804 |
Other assets | 10,187 | 311 |
Total assets | 686,244 | 576,732 |
Current liabilities | ||
Accounts payable | 8,304 | 3,797 |
Accrued expenses | 7,832 | 9,662 |
Deferred rent | 315 | |
Lease liabilities | 2,197 | |
Deferred revenue | 45,579 | 40,079 |
Income tax payable | 400 | |
Total current liabilities | 64,312 | 53,853 |
Deferred rent, net of current portion | 1,198 | |
Lease liabilities, net of current portion | 9,082 | |
Deferred revenue, net of current portion | 2,613 | |
Total liabilities | 76,007 | 55,051 |
Commitments and contingencies | ||
Stockholders' equity | ||
Preferred stock, $0.01 par value: 10,000,000 authorized shares; -0- issued and outstanding shares at September 30, 2019 and December 31, 2018 | ||
Common stock, $0.01 par value: 200,000,000 authorized shares at September 30, 2019 and December 31, 2018; 56,714,788 issued and outstanding at September 30, 2019 and 56,279,542 issued and outstanding at December 31, 2018 | 567 | 563 |
Additional paid-in capital | 877,724 | 845,366 |
Accumulated other comprehensive income (loss) | 1,436 | (971) |
Accumulated deficit | (269,490) | (323,277) |
Total stockholders' equity | 610,237 | 521,681 |
Total liabilities and stockholders' equity | $ 686,244 | $ 576,732 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - $ / shares | Sep. 30, 2019 | Dec. 31, 2018 |
Condensed Balance Sheets | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 200,000,000 | 200,000,000 |
Common stock, shares issued | 56,714,788 | 56,279,542 |
Common stock, shares outstanding | 56,714,788 | 56,279,542 |
Statements of Comprehensive Inc
Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Revenue | ||||
Collaborations, licenses, milestones, and royalties | $ 21,760 | $ 29,039 | $ 153,184 | $ 29,039 |
Operating expenses | ||||
Research and development | 29,770 | 20,953 | 91,250 | 70,371 |
General and administrative | 6,266 | 7,435 | 17,537 | 16,955 |
Total operating expenses | 36,036 | 28,388 | 108,787 | 87,326 |
Income (loss) from operations | (14,276) | 651 | 44,397 | (58,287) |
Other income (expenses) | ||||
Interest income, net | 3,699 | 2,642 | 10,201 | 6,279 |
Other income (expense), net | 3 | (143) | (211) | (202) |
Total other income, net | 3,702 | 2,499 | 9,990 | 6,077 |
Net income (loss) before income tax expense (benefit) | (10,574) | 3,150 | 54,387 | (52,210) |
Income tax expense (benefit) | (350) | 600 | ||
Net income (loss) | (10,224) | 3,150 | 53,787 | (52,210) |
Other comprehensive income (loss) | ||||
Net unrealized gain (loss) on marketable securities | (193) | (330) | 2,407 | (530) |
Comprehensive income (loss) | $ (10,417) | $ 2,820 | $ 56,194 | $ (52,740) |
Basic net income (loss) per common share | $ (0.18) | $ 0.06 | $ 0.95 | $ (0.98) |
Diluted net income (loss) per common share | $ (0.18) | $ 0.05 | $ 0.92 | $ (0.98) |
Basic weighted average common shares outstanding | 56,643,075 | 55,974,080 | 56,449,678 | 53,165,774 |
Diluted weighted average common shares outstanding | 56,643,075 | 58,313,002 | 58,365,158 | 53,165,774 |
Statement of Stockholders' Equi
Statement of Stockholders' Equity - USD ($) $ in Thousands | Scenario, Previously ReportedCommon Stock | Scenario, Previously ReportedAdditional Paid-in Capital | Scenario, Previously ReportedAccumulated Other Comprehensive Loss | Scenario, Previously ReportedAccumulated Deficit | Scenario, Previously Reported | Restatement AdjustmentAccumulated Deficit | Restatement Adjustment | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Total |
Increase (Decrease) in Stockholders' Equity | ||||||||||||
Adoption of ASC 606 | $ 34,418 | $ 34,418 | ||||||||||
Balance, revised | $ 470 | $ 570,670 | $ (1,808) | $ (252,868) | $ 316,464 | |||||||
Balance at Dec. 31, 2017 | $ 470 | $ 570,670 | $ (1,808) | $ (287,286) | $ 282,046 | |||||||
Balance (in shares) at Dec. 31, 2017 | 47,002,488 | 47,002,488 | ||||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||||||
Sale of common stock, net of issuance cost | $ 84 | 245,421 | 245,505 | |||||||||
Sale of common stock, net of issuance cost (in shares) | 8,395,000 | |||||||||||
Issuance of common stock upon exercise of stock awards | $ 2 | 1,108 | 1,110 | |||||||||
Issuance of common stock upon exercise of stock awards (in shares) | 219,387 | |||||||||||
Comprehensive income (loss) | (393) | (29,493) | (29,886) | |||||||||
Stock-based compensation expense | 4,471 | 4,471 | ||||||||||
Balance at Mar. 31, 2018 | $ 556 | 821,670 | (2,201) | (282,361) | 537,664 | |||||||
Balance (in shares) at Mar. 31, 2018 | 55,616,875 | |||||||||||
Balance at Dec. 31, 2017 | $ 470 | $ 570,670 | $ (1,808) | $ (287,286) | $ 282,046 | |||||||
Balance (in shares) at Dec. 31, 2017 | 47,002,488 | 47,002,488 | ||||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||||||
Comprehensive income (loss) | (52,740) | |||||||||||
Balance at Sep. 30, 2018 | $ 562 | 839,128 | (2,338) | (305,080) | 532,272 | |||||||
Balance (in shares) at Sep. 30, 2018 | 56,212,449 | |||||||||||
Balance at Mar. 31, 2018 | $ 556 | 821,670 | (2,201) | (282,361) | 537,664 | |||||||
Balance (in shares) at Mar. 31, 2018 | 55,616,875 | |||||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||||||
Sale of common stock, net of issuance cost | (1) | (1) | ||||||||||
Issuance of common stock upon exercise of stock awards | $ 2 | 1,803 | 1,805 | |||||||||
Issuance of common stock upon exercise of stock awards (in shares) | 177,883 | |||||||||||
Issuance of common stock under the Employee Stock Purchase Plan | 504 | 504 | ||||||||||
Issuance of common stock under the Employee Stock Purchase Plan (in shares) | 26,552 | |||||||||||
Comprehensive income (loss) | 193 | (25,869) | (25,676) | |||||||||
Stock-based compensation expense | 4,882 | 4,882 | ||||||||||
Balance at Jun. 30, 2018 | $ 558 | 828,858 | (2,008) | (308,230) | 519,178 | |||||||
Balance (in shares) at Jun. 30, 2018 | 55,821,310 | |||||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||||||
Issuance of common stock upon exercise of stock awards | $ 4 | 4,150 | 4,154 | |||||||||
Issuance of common stock upon exercise of stock awards (in shares) | 391,139 | |||||||||||
Comprehensive income (loss) | (330) | 3,150 | 2,820 | |||||||||
Stock-based compensation expense | 6,120 | 6,120 | ||||||||||
Balance at Sep. 30, 2018 | $ 562 | 839,128 | (2,338) | (305,080) | 532,272 | |||||||
Balance (in shares) at Sep. 30, 2018 | 56,212,449 | |||||||||||
Balance at Dec. 31, 2018 | $ 563 | 845,366 | (971) | (323,277) | 521,681 | |||||||
Balance (in shares) at Dec. 31, 2018 | 56,279,542 | |||||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||||||
Issuance of common stock upon exercise of stock awards | $ 1 | 666 | 667 | |||||||||
Issuance of common stock upon exercise of stock awards (in shares) | 58,536 | |||||||||||
Issuance of restricted stock units (in shares) | 11,311 | |||||||||||
Comprehensive income (loss) | 1,316 | 80,045 | 81,361 | |||||||||
Stock-based compensation expense | 5,856 | 5,856 | ||||||||||
Balance at Mar. 31, 2019 | $ 564 | 851,888 | 345 | (243,232) | 609,565 | |||||||
Balance (in shares) at Mar. 31, 2019 | 56,349,389 | |||||||||||
Balance at Dec. 31, 2018 | $ 563 | 845,366 | (971) | (323,277) | 521,681 | |||||||
Balance (in shares) at Dec. 31, 2018 | 56,279,542 | |||||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||||||
Comprehensive income (loss) | 56,194 | |||||||||||
Balance at Sep. 30, 2019 | $ 567 | 877,724 | 1,436 | (269,490) | 610,237 | |||||||
Balance (in shares) at Sep. 30, 2019 | 56,714,788 | |||||||||||
Balance at Mar. 31, 2019 | $ 564 | 851,888 | 345 | (243,232) | 609,565 | |||||||
Balance (in shares) at Mar. 31, 2019 | 56,349,389 | |||||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||||||
Issuance of common stock upon exercise of stock awards | $ 1 | 3,238 | 3,239 | |||||||||
Issuance of common stock upon exercise of stock awards (in shares) | 143,504 | |||||||||||
Issuance of common stock under the Employee Stock Purchase Plan | 734 | 734 | ||||||||||
Issuance of common stock under the Employee Stock Purchase Plan (in shares) | 36,505 | |||||||||||
Comprehensive income (loss) | 1,284 | (16,034) | (14,750) | |||||||||
Stock-based compensation expense | 9,303 | 9,303 | ||||||||||
Balance at Jun. 30, 2019 | $ 565 | 865,163 | 1,629 | (259,266) | 608,091 | |||||||
Balance (in shares) at Jun. 30, 2019 | 56,529,398 | |||||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||||||
Issuance of common stock upon exercise of stock awards | $ 2 | 3,047 | 3,049 | |||||||||
Issuance of common stock upon exercise of stock awards (in shares) | 185,390 | |||||||||||
Comprehensive income (loss) | (193) | (10,224) | (10,417) | |||||||||
Stock-based compensation expense | 9,514 | 9,514 | ||||||||||
Balance at Sep. 30, 2019 | $ 567 | $ 877,724 | $ 1,436 | $ (269,490) | $ 610,237 | |||||||
Balance (in shares) at Sep. 30, 2019 | 56,714,788 |
Statements of Cash Flows
Statements of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Cash flows from operating activities | ||
Net income (loss) | $ 53,787 | $ (52,210) |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
Depreciation and amortization | 3,073 | 2,368 |
Amortization of premium and accretion of discount on marketable securities | (3,333) | 68 |
Stock-based compensation | 24,673 | 15,473 |
Abandonment of capitalized intangible assets | 115 | 118 |
Loss on disposal of assets | 8 | 110 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 5,903 | (1,320) |
Interest receivable | (3) | (624) |
Contract asset | (15,000) | |
Prepaid expenses and other assets | 2,843 | (6,535) |
Accounts payable | 4,508 | (886) |
Accrued expenses | (1,830) | 192 |
Income taxes | 1,204 | (156) |
Deferred rent | (1,513) | 466 |
Lease liabilities and ROU assets | 1,403 | |
Deferred revenue | 8,113 | (20,039) |
Net cash provided by (used in) operating activities | 83,951 | (62,975) |
Cash flows from investing activities | ||
Purchase of marketable securities | (352,174) | (331,126) |
Purchase of intangible assets | (2,932) | (1,302) |
Purchase of property and equipment | (4,443) | (4,425) |
Proceeds from maturities of marketable securities | 292,852 | 165,134 |
Repayment of loan | 86 | |
Net cash used in investing activities | (66,697) | (171,633) |
Cash flows from financing activities | ||
Proceeds from issuance of common stock upon exercise of stock awards | 6,955 | 7,068 |
Proceeds from issuance of common stock under the Employee Stock Purchase Plan | 734 | 504 |
Proceeds from issuance of common stock | 260,245 | |
Common stock issuance costs | (14,741) | |
Net cash provided by financing activities | 7,689 | 253,076 |
Net increase in cash and cash equivalents | 24,943 | 18,468 |
Cash and cash equivalents, beginning of period | 26,246 | 16,528 |
Cash and cash equivalents, end of period | 51,189 | 34,996 |
Cash paid during the period for: | ||
Interest | 11 | 9 |
Income taxes | 200 | 170 |
Supplemental disclosures of non-cash investing activities | ||
Unrealized gain (loss) on marketable securities, net of tax | $ 2,407 | $ (530) |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2019 | |
Summary of Significant Accounting Policies | |
Summary of Significant Accounting Policies | 1. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited interim financial statements for Xencor, Inc. (the Company, Xencor, we or us) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. Certain amounts in the prior period financial statements have been revised to conform to the presentation of the current period financial statements. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. The preparation of interim financial statements requires the use of management’s estimates and assumptions that affect reported amounts of assets and liabilities at the date of the interim financial statements and the reported revenues and expenditures during the reported periods. These interim financial results are not necessarily indicative of the results expected for the full fiscal year or for any subsequent interim period. The accompanying unaudited interim financial statements and related notes should be read in conjunction with the audited financial statements and notes thereto included in the Company’s 2018 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2019. Use of Estimates The preparation of interim financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, other comprehensive gain (loss) and the related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to its accrued clinical trial and manufacturing development expenses, stock-based compensation expense, intangible assets and related amortization. Significant estimates in these interim financial statements include estimates made for royalties and accrued research and development expenses, stock-based compensation expenses, intangible assets and related amortization, estimated standalone selling price of performance obligations, the likelihood of recognizing variable consideration, and recoverability of deferred tax assets. Intangible Assets The Company maintains definite-lived intangible assets related to certain capitalized costs of acquired licenses and third-party costs incurred in establishing and maintaining its intellectual property rights to its platform technologies and development candidates. These assets are amortized over their useful lives, which are estimated to be the remaining patent life or the contractual term of the license. The straight-line method is used to record amortization expense. The Company assesses its intangible assets for impairment if indicators are present or changes in circumstances suggest that impairment may exist. There were no impairment charges recorded for the nine months ended September 30, 2019 and 2018. The Company capitalizes certain in-process intangible assets that are abandoned when they are no longer pursued or used in current research activities. There was no material abandonment of in-process intangible assets during the nine months ended September 30, 2019 or 2018. Marketable Securities The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The Company invests its excess cash primarily in marketable debt securities issued by investment grade institutions. The Company considers its marketable debt securities to be available-for-sale. These assets are carried at fair value and the unrealized gains and losses are included in accumulated other comprehensive income (loss). Accrued interest on marketable debt securities is included in marketable securities. If a decline in the value of a marketable debt security in the Company’s investment portfolio is deemed to be other-than-temporary, the Company writes down the security to its current fair value and recognizes a loss as a charge against income. The Company reviews its portfolio of marketable debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost are other-than-temporary. Recent Accounting Pronouncements Pronouncements Adopted in 2019 Effective January 1, 2019, the Company adopted Accounting Standards Codification Topic 842 (ASC 842), Leases At inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases with a term of one year or longer where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit with such leases is typically not readily determined. The Company has determined the appropriate incremental borrowing rate by reference to an estimate of the current market borrowing rate for a collateralized asset over a similar term as the lease term. The new standard impacts our reporting on the leases on our facilities in Monrovia and San Diego. Under ASC 842, tenant allowances under such operating leases are no longer tracked separately as a deferred rent liability; instead, it is integrated as part of the ROU asset. As a result, we recorded an adjustment to the beginning balance for deferred rent liability and adopted the use of ROU asset and lease liability. We recorded lease liabilities of $12.7 million and ROU assets of $11.4 million for lease agreements in effect as of January 1, 2019. The ROU asset is included in Other assets on the balance sheet as of September 30, 2019. This resulted in an increase to the beginning balance on both assets and liabilities after the adjustment of $11.2 million, with no impact on our retained earnings. Effective January 1, 2019, the Company adopted ASU No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payments issued to nonemployees for goods and services. The standard requires a modified retrospective transition approach, with a cumulative adjustment to retained earnings as of adoption date, for all liability-classified awards that have not been settled as of the adoption date and equity-classified nonemployee awards for which a measurement date has not been established. The adoption of this standard did not have any impact on the Company’s financial statements. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 9 Months Ended |
Sep. 30, 2019 | |
Fair Value of Financial Instruments | |
Fair Value of Financial Instruments | 2. Fair Value of Financial Instruments Financial instruments included in the financial statements include cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses. Marketable securities and cash equivalents are carried at fair value. The fair value of the other financial instruments closely approximates their fair value due to their short-term maturities. The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification ASC 820, Fair Value Measurements and Disclosures Level 1— Level 2— Level 3— The Company measures the fair value of financial assets using the highest level of inputs that are reasonably available as of the measurement date. The assets recorded at fair value are classified within the hierarchy as follows for the periods reported (in thousands): September 30, 2019 December 31, 2018 Total Total Fair Value Level 1 Level 2 Fair Value Level 1 Level 2 Money Market Funds $ 30,603 $ 30,603 $ — $ 18,270 $ 18,270 $ — Corporate Securities 217,702 — 217,702 104,967 — 104,967 Government Securities 351,585 — 351,585 399,256 — 399,256 $ 599,890 $ 30,603 $ 569,287 $ 522,493 $ 18,270 $ 504,223 Our policy is to record transfers of assets between Level 1 and Level 2 at their fair values as of the end of each reporting period, consistent with the date of the determination of fair value. During the three and nine months ended September 30, 2019 and 2018, there were no transfers between Level 1 and Level 2. The Company does not have any Level 3 assets or liabilities. |
Net Income (Loss) Per Share
Net Income (Loss) Per Share | 9 Months Ended |
Sep. 30, 2019 | |
Net Income (Loss) Per Share | |
Net Income (Loss) Per Share | 3. Net Income (Loss) Per Share We compute basic net income (loss) per common share by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period without consideration of common stock equivalents. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants, employee stock purchase plan (ESPP) and restricted stock units (RSUs). Potentially dilutive securities consisting of stock issuable under options, ESPP and RSUs are not included in the per common share calculation in periods where there is a net loss where the inclusion of such shares would have had an antidilutive effect. Basic and diluted net income (loss) per common share is computed as follows (in thousands except share and per share data): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 (in thousands, except share and per share data) Numerator: Net income (loss) attributable to common stockholders $ (10,224) $ 3,150 $ 53,787 $ (52,210) Denominator: Weighted-average common shares outstanding used in computing basic net income (loss) 56,643,075 55,974,080 56,449,678 53,165,774 Weighted-average common shares outstanding used in computing diluted net income (loss) 56,643,075 58,313,002 58,365,158 53,165,774 Basic net income (loss) per common share $ (0.18) $ 0.06 $ 0.95 $ (0.98) Diluted net income (loss) per common share $ (0.18) $ 0.05 $ 0.92 $ (0.98) For the three months ended September 30, 2019 and the nine months ended September 30, 2018, all outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share as the effect of including such securities would have been antidilutive. For the three months ended September 30, 2018 and the nine months ended September 30, 2019, potentially dilutive securities were included in the diluted net income per common share calculation. The numbers of common stock equivalents that were included in the calculation of the weighted-average common shares outstanding used in computing diluted net income per common share are as follows: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 (in thousands) (in thousands) Employee stock purchase plan shares — — 20 — Options to purchase common stock and RSU grants — 2,339 1,895 — — 2,339 1,915 — The table below summarizes the number of common stock equivalents that were excluded in the calculation of the weighted-average common shares outstanding used in computing diluted net income (loss) because the inclusion of such shares would have had an antidilutive effect as follows: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 (in thousands) (in thousands) Employee stock purchase plan shares 6 — — — Options to purchase common stock and RSU grants 2,261 — — 1,884 2,267 — — 1,884 |
Comprehensive Income (Loss)
Comprehensive Income (Loss) | 9 Months Ended |
Sep. 30, 2019 | |
Comprehensive Income (Loss) | |
Comprehensive Income (Loss) | 4. Comprehensive Income (Loss) Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss). For the three and nine months ended September 30, 2019 and 2018, the only component of other comprehensive income (loss) is net unrealized gain (loss) on marketable securities. There were no material reclassifications out of accumulated other comprehensive income (loss) during the three and nine months ended September 30, 2019 and 2018. |
Marketable Securities
Marketable Securities | 9 Months Ended |
Sep. 30, 2019 | |
Marketable Securities | |
Marketable Securities | 5. Marketable Securities The Company’s marketable debt securities held as of September 30, 2019 and December 31, 2018 are summarized below: Gross Gross Amortized Unrealized Unrealized September 30, 2019 Cost Gains Losses Fair Value (in thousands) Money Market Funds $ 30,603 $ — $ — $ 30,603 Corporate Securities 217,484 228 (10) 217,702 Government Securities 350,358 1,227 — 351,585 $ 598,445 $ 1,455 $ (10) $ 599,890 Reported as Cash and cash equivalents $ 30,603 Marketable securities 569,287 Total investments $ 599,890 Gross Gross Amortized Unrealized Unrealized December 31, 2018 Cost Gains Losses Fair Value (in thousands) Money Market Funds $ 18,270 $ — $ — $ 18,270 Corporate Securities 105,311 1 (345) 104,967 Government Securities 399,873 187 (804) 399,256 $ 523,454 $ 188 $ (1,149) $ 522,493 Reported as Cash and cash equivalents $ 18,270 Marketable securities 504,223 Total investments $ 522,493 The maturities of the Company’s marketable debt securities are as follows: Amortized Estimated September 30, 2019 Cost Fair Value (in thousands) Mature in one year or less $ 494,248 $ 495,292 Mature within two years 73,594 73,995 $ 567,842 $ 569,287 The unrealized losses on available-for-sale investments and their related fair values as of September 30, 2019 and December 31, 2018 are as follows: Less than 12 months 12 months or greater Unrealized Unrealized September 30, 2019 Fair value losses Fair value losses (in thousands) Corporate Securities $ 3,037 $ (1) $ 21,409 $ (9) Government Securities 15,606 (1) — — $ 18,643 $ (2) $ 21,409 $ (9) Less than 12 months 12 months or greater Unrealized Unrealized December 31, 2018 Fair value losses Fair value losses (in thousands) Corporate Securities $ 84,666 $ (310) $ 17,805 $ (35) Government Securities 176,225 (672) 116,830 (132) $ 260,891 $ (982) $ 134,635 $ (167) The unrealized losses from the listed securities are due to a change in the interest rate environment and not a change in the credit quality of the securities. The Company does not intend to sell these securities, and it is not more likely than not that the Company will be required to sell the securities before recovery of the amortized cost basis. Therefore, the Company did not consider these securities to be other-than-temporarily impaired as of September 30, 2019 or December 31, 2018. |
Sale of Additional Common Stock
Sale of Additional Common Stock | 9 Months Ended |
Sep. 30, 2019 | |
Sale of Additional Common Stock | |
Sale of Additional Common Stock | 6. Sale of Additional Common Stock In March 2018, we completed the sale of 8,395,000 shares of common stock which included shares issued pursuant to our underwriters’ exercise of their over-allotment option pursuant to a follow-on financing. We received net proceeds of $245.5 million after underwriting discounts, commissions and offering expenses. |
Stock-Based Compensation
Stock-Based Compensation | 9 Months Ended |
Sep. 30, 2019 | |
Stock-Based Compensation | |
Stock-Based Compensation | 7. Stock Based Compensation Our Board of Directors (the Board) and the requisite stockholders previously approved the 2010 Equity Incentive Plan (the 2010 Plan). In October 2013, the Board approved the 2013 Equity Incentive Plan (the 2013 Plan) and in November 2013 our stockholders approved the 2013 Plan which became effective as of December 3, 2013. As of December 2, 2013, we suspended the 2010 Plan and no additional awards may be granted under the 2010 Plan. Any shares of common stock covered by awards granted under the 2010 Plan that terminate after December 2, 2013 by expiration, forfeiture, cancellation or other means without the issuance of such shares will be added to the 2013 Plan reserve. As of September 30, 2019, the total number of shares of common stock available for issuance under the 2013 Plan is 11,434,273, which includes 2,684,456 shares of common stock that were available for issuance under the 2010 Plan as of the effective date of the 2013 Plan. Unless otherwise determined by the Board, beginning January 1, 2014, and continuing until the expiration of the 2013 Plan, the total number of shares of common stock available for issuance under the 2013 Plan will automatically increase annually on January 1 of each year by 4% of the total number of issued and outstanding shares of common stock as of December 31 of the immediate preceding year. Pursuant to approval by the Board on January 1, 2019, the total number of shares of common stock available for issuance under the 2013 Plan was increased by 2,251,181 shares. As of September 30, 2019, a total of 8,669,662 options have been granted under the 2013 Plan. In November 2013, the Board and our stockholders approved the 2013 Employee Stock Purchase Plan (ESPP), which became effective as of December 5, 2013. We have reserved a total of 581,286 shares of common stock for issuance under the ESPP. Unless otherwise determined by the Board, beginning on January 1, 2014, and continuing until the expiration of the ESPP, the total number of shares of common stock available for issuance under the ESPP will automatically increase annually on January 1 by the lesser of (i) 1% of the total number of issued and outstanding shares of common stock as of December 31 of the immediately preceding year, or (ii) 621,814 shares of common stock. Pursuant to approval by our Board of Directors, there was no increase in the number of authorized shares in the ESPP in 2019. As of September 30, 2019, we have issued a total of 386,221 shares of common stock under the ESPP. During the nine months ended September 30, 2019, the Company awarded 39,666 Restricted Stock Units (RSUs) to certain employees. Vesting of these awards is in three equal annual installments and is contingent on continued service to the Company. The fair value of these awards is determined based on the intrinsic value of the stock on the date of grant and will be recognized as stock-based compensation expense over the requisite service period. As of September 30, 2019, we have granted a total of 73,599 shares of common stock subject to RSUs. Total employee, director and non-employee stock-based compensation expense recognized for the three and nine months ended September 30, 2019 and 2018 are as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 General and administrative $ 2,474 $ 2,732 $ 6,337 $ 6,037 Research and development 7,040 3,388 18,336 9,436 $ 9,514 $ 6,120 $ 24,673 $ 15,473 Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Stock options $ 9,117 $ 5,832 $ 23,588 $ 14,723 ESPP 217 209 630 562 Restricted stock units 180 79 455 188 $ 9,514 $ 6,120 $ 24,673 $ 15,473 The following table summarizes option activity under our stock plans and related information: Weighted Weighted Average Average Number of Exercise Remaining Aggregate Shares subject Price Contractual Intrinsic to outstanding (Per Term Value options Share) (in years) (in thousands) Balances at December 31, 2018 5,966,928 $ 19.71 7.51 Options granted 1,918,375 $ 35.76 Options forfeited (266,780) $ 31.36 Options exercised (387,430) $ 17.95 Balances at September 30, 2019 7,231,093 $ 23.63 7.47 $ 78,789 Exercisable 3,831,677 $ 17.25 6.28 $ 63,736 We calculate the intrinsic value as the difference between the exercise price of the options and the closing price of common stock of $33.73 per share as of September 30, 2019. Weighted average fair value of options granted during the nine-month periods ended September 30, 2019 and 2018 were $20.71 and $17.57 per share, respectively. There were 1,679,400 options granted during the nine-month period ended September 30, 2018. We estimated the fair value of each stock option using the Black-Scholes option-pricing model based on the date of grant of such stock option with the following weighted average assumptions for the three and nine months ended September 30, 2019 and 2018: Options Options Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (years) 6.0 6.1 6.0 6.1 Expected volatility 60.8 % 72.8 % 61.2 % 73.1 % Risk-free interest rate 1.52 % 2.87 % 2.33 % 2.56 % Expected dividend yield — % — % — % — % ESPP ESPP Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (years) 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 Expected volatility 55.0 - 71.4 % 61.2 - 71.4 % 55.0 - 71.4 % 61.2 - 71.4 % Risk-free interest rate 1.47 - 2.70 % 1.47 - 2.41 % 1.47 - 2.70 % 1.47 - 2.41 % Expected dividend yield — % — % — % — % As of September 30, 2019, the unamortized compensation expense related to unvested stock options was $56.6 million. The remaining unamortized compensation expense will be recognized over the next 2.45 years. As of September 30, 2019, the unamortized compensation expense under our ESPP was $0.1 million. The remaining unamortized expense will be recognized over the next 0.2 years. The following table summarizes the RSU activity for the nine-month period ended September 30, 2019: Weighted Restricted Average Grant Stock Date Fair Value Units (Per unit) Unvested at December 31, 2018 33,933 $ 27.64 Granted 39,666 35.94 Vested (11,311) 27.64 Forfeited (4,182) 31.12 Unvested at September 30, 2019 58,106 $ 33.05 As of September 30, 2019, the unamortized compensation expense related to unvested restricted stock units was $1.5 million. The remaining unamortized expense will be recognized over the next 2.2 years. |
Leases
Leases | 9 Months Ended |
Sep. 30, 2019 | |
Leases | |
Leases | 8. Leases The Company leases office and laboratory space in Monrovia, CA under a lease that continues through June 2020, with an option to renew for an additional five years. The Company also leases office space in San Diego, CA through July 2020 which includes an option to renew for an additional five years. The Company assesses that it is unlikely to exercise the option to extend this lease. The Company leases additional office space in San Diego, CA through August 2022, with an option to extend for an additional five years. The Company assesses that it is unlikely to exercise the option to extend the lease term. The Company’s lease agreements do not contain any residual value guarantees or restrictive covenants. As of September 30, 2019, the Company did not have additional operating leases that have not yet commenced. The following table reconciles the undiscounted cash flows for the operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet (in thousands): Years ending December 31, For the remainder of 2019 $ 698 2020 2,703 2021 2,587 2022 2,208 2023 1,352 2024 1,371 Thereafter 2,282 Total undiscounted lease payments 13,201 Less: Imputed interest (1,922) Present value of lease payments $ 11,279 Lease liabilities - short-term $ 2,197 Lease liabilities - long-term 9,082 Total lease liabilities $ 11,279 Our operating lease cost and the cash payments for operating leases for the nine months ended September 30, 2019 were $2.0 million and $1.9 million, respectively. Rent expense for the nine months ended September 30, 2018 was $1.9 million. At September 30, 2019, the weighted-average remaining lease term for operating leases was 5.7 years, and the weighted average discount rate for operating leases is 5.5%. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2019 | |
Commitments and Contingencies | |
Commitments and Contingencies | 9. Commitments and Contingencies From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred. We are obligated to make future payments to third parties under in-license agreements, including sublicense fees, royalties, and payments that become due and payable on the achievement of certain development and commercialization milestones. As the amount and timing of sublicense fees and the achievement and timing of these milestones are not probable and estimable, such commitments have not been included on our balance sheet. We have also entered into agreements with third-party vendors which will require us to make future payments upon the delivery of goods and services in future periods. |
Collaboration and Licensing Agr
Collaboration and Licensing Agreements | 9 Months Ended |
Sep. 30, 2019 | |
Collaboration and Licensing Agreements | |
Collaboration and Licensing Agreements | 10. Collaboration and Licensing Agreements The following is a summary description of the material revenue arrangements, including arrangements that generated revenue in the nine months ended September 30, 2019 and 2018. Genentech In February 2019, the Company entered into a collaboration and license agreement (the Genentech Agreement) with Genentech, Inc. and F. Hoffman-La Roche Ltd (collectively, Genentech) for the development and commercialization of novel IL-15 collaboration products (Collaboration Products), including XmAb24306, the Company’s IL-15/IL-15Ra candidate. The Genentech Agreement became effective March 8, 2019. Under the terms of the Genentech Agreement, Genentech received an exclusive worldwide license to XmAb24306 and other Collaboration Products, including any new IL-15 programs identified during the joint research collaboration. Genentech and Xencor will jointly collaborate on worldwide development of XmAb24306 and other Collaboration Products with Genentech maintaining all worldwide commercialization rights, subject to Xencor having an option to co-promote in the United States. Xencor has the right to perform clinical studies of Collaboration Products in combination with other therapeutic agents at its own cost, subject to certain requirements. The term of the Genentech Agreement will continue on a program-by-program and country-by-country basis until there are no remaining payment obligations from Genentech to Xencor with respect to Collaboration Products. Genentech may terminate the Genentech Agreement in its entirety or on a Collaboration Product-by-Collaboration Product basis by providing prior written notice. Xencor may terminate the Agreement on a Collaboration Product-by-Collaboration Product basis if Genentech fails to spend a defined minimum amount on research, development, or commercialization activities for that Collaboration Product. In the event of a termination of any individual Collaboration Product or the Genentech Agreement in its entirety, the relevant rights revert to Xencor. The Company received a $120.0 million upfront payment and is eligible to receive up to an aggregate of $160.0 million in clinical milestone payments for each Collaboration Product that advances to Phase 3 clinical trials. The Company is also eligible to receive 45% share of net profits for sales of XmAb24306 and other Collaboration Products, while also sharing in net losses at the same percentage rate. The parties will jointly share in development and commercialization costs for all programs designated as a development program under the Genentech Agreement at the same percentage rate, while Genentech will bear launch costs entirely. The initial 45% profit-cost share percent is subject to ratchet down at the Company’s discretion and convertible to a royalty under certain circumstances. Pursuant to the Genentech Agreement, XmAb24306 is designated as a development program and all costs incurred for developing XmAb24306 from the effective date of the Genentech Agreement are being shared with Genentech under the initial cost-sharing percentage. Under the Genentech Agreement, the Company and Genentech will conduct joint research activities for a two-year period to identify and discover additional IL-15 candidates developed from the Company’s cytokine and bispecific technologies. The two-year research term may be extended an additional year if both parties agree. The Company and Genentech are each responsible for their own costs in conducting the research activities. The Company will receive a $20.0 million development milestone for each new Collaboration Product that is identified from the research efforts and advances into a Phase 1 clinical trial. The Company evaluated the Genentech Agreement under the provisions of ASU No. 2014-09, Revenue from Contracts with Customers Collaborative Arrangements The Company identified the following performance obligations under the Genentech Agreement: (i) the license of XmAb24306 and (ii) research services during a two-year period to identify up to potentially nine additional IL-15 candidates, each a separate research program and a separate performance obligation. The Company determined that the license and each of the potential research programs are separate performance obligations because they are capable of being distinct and are distinct in the context of the Genentech Agreement. The license to XmAb24306 has standalone functionality as Genentech has exclusive worldwide rights to the program, including the right to sublicense to third parties. Genentech has significant experience and capabilities in developing and commercializing drug candidates similar to XmAb24306, and Genentech is capable of performing these activities without the Company’s involvement. Upon the transfer of the license of XmAb24306, Genentech could develop and commercialize XmAb24306 without further assistance from the Company. The Company determined that the research services for each potential additional IL-15 candidate and research program were separate standalone performance obligations. The Genentech Agreement provides an outline of an integrated research plan for the programs to be conducted by the two companies, and the research activities are separate and distinct from the license to XmAb24306. The Company determined the standalone selling price of the license to be $114.4 million using the adjusted market assessment approach considering similar collaboration and license agreements and transactions. The standalone selling price for the research activities for all nine of the potential IL-15 programs to be performed during the research term was determined to be $8.5 million using the expected cost approach which was derived from the Company’s experience and information from providing similar research activities to other parties. The Company determined that the transaction price of the Genentech Agreement at inception was $120.0 million consisting of the upfront payment. The potential milestones are not included in the transaction price as these are contingent on future events and the Company would not recognize these in revenue until it is not probable that these would not result in significant reversal of revenue amounts in future periods. The Company will re-assess the transaction price at each reporting period and when event outcomes are resolved or changes in circumstances occur. The Company allocated the transaction price to each of the separate performance obligation using the relative standalone selling price with $111.7 million allocated to the license to XmAb24306 and $8.3 million allocated to the research services. The Company recognized the $111.7 million allocated to the license when it satisfied its performance obligation and transferred the license to Genentech in March 2019. The license was transferred upon the effective date of the Genentech Agreement and when the Company subsequently transferred certain data related to the program to Genentech. The $8.3 million allocated to the research activities is being recognized over a period of time through the end of the research term that services are rendered as we determine that the input method is the appropriate approach to recognize income for such services. A total of $1.6 million of revenue related to the research activities was recognized in the nine-month period ended September 30, 2019. For the three and nine months ended September 30, 2019, we recognized $0.7 million and $113.2 million of income, respectively, from the Genentech Agreement. As of September 30, 2019, there is a $0.5 million payable related to cost-sharing development activities during the third quarter of 2019 for the XmAb24306 program. There is $6.8 million in deferred revenue as of September 30, 2019 which reflects our obligation to perform research services during the research term. Astellas Effective March 29, 2019, the Company entered into a Research and License Agreement (Astellas Agreement) with Astellas Pharma Inc. (Astellas) pursuant to which the Company and Astellas will conduct a discovery program to characterize compounds and products for development and commercialization. Under the Astellas Agreement, Astellas was granted a worldwide exclusive license, with the right to sublicense products in the field created by the research activities. Pursuant to the Astellas Agreement, the Company will apply its bispecific Fc technology to research antibodies provided by Astellas to generate bispecific antibody candidates and will conduct limited testing and characterization of the bispecific candidates and return the candidates to Astellas for development and commercialization. The activities will be conducted under a research plan agreed to by both parties to the Astellas Agreement. Astellas will assume full responsibility for development and commercialization of the antibody candidate. Pursuant to the Astellas Agreement, the Company received an upfront payment of $15.0 million and is eligible to receive up to $240.0 million in milestones which include $32.5 million in development milestones, $57.5 million in regulatory milestones and $150.0 million in sales milestones. If commercialized, the Company is eligible to receive royalties on net sales that range from the high-single to low-double digit percentages. We evaluated the Astellas Agreement under ASC 606 and identified the performance obligations under the Agreement to be (i) delivery of bispecific antibodies to Astellas from the antigen provided by Astellas and (ii) research activities against the bispecific antibodies as outlined in the research plan. The Company determined that the license to the bispecific antibodies is not a separate performance obligation because it is not capable of being distinct, the license to the antibodies cannot be separated from the underlying antibodies. Astellas will control and benefit from the antibodies that are delivered. The Astellas Agreement provides Astellas the right to sublicense the antibody to third parties and Astellas has significant experience and capabilities in developing and commercializing clinical candidates and is capable of performing these activities from the delivered antibodies without the Company’s involvement. The Company determined the standalone selling price of the bispecific deliverable to be $17.1 million using the income approach by calculating a risk adjusted net present value of the potential revenue that could be earned from the arrangement. The standalone selling price for the research activities to be performed was determined to be $1.4 million using the expected cost approach which was derived from the Company’s experience and information from providing similar research activities to other customers. The Company determined that the transaction price of the Astellas Agreement at inception was $15.0 million consisting of the upfront payment. The potential milestones are not included in the transaction price as these are contingent on future events and the Company would not recognize these in revenue until it is not probable that these would not result in significant reversal of revenue amounts in future periods. The Company will re-assess the transaction price at each reporting period and when event outcomes are resolved or changes in circumstances occur. The Company allocated the transaction price to each of the separate performance obligations using the relative standalone selling price with $13.6 million allocated to delivery of the bispecific antibodies and $1.4 million allocated to the research activities. The Company recognized the $13.6 million allocated to the bispecific antibodies when it satisfied its performance obligation and transferred the bispecific antibodies to Astellas in June 2019. Astellas transferred the research antibodies to the Company and the Company applied its bispecific technologies to and transferred the completed antibodies to Astellas. The $1.4 million allocated to the research activities is being recognized as the research services are being completed over the period of time the Company expects to complete the activities under the research plan. No revenue was recognized under this arrangement for the three months ended September 30, 2019. For the nine months ended September 30, 2019, we recognized $13.8 million related to the arrangement and there is $1.2 million in deferred revenue as of September 30, 2019 related to our obligation to complete research activities under the Astellas Agreement. Novartis In June 2016, the Company entered into a Collaboration and License Agreement (Novartis Agreement) with Novartis Institutes for BioMedical Research, Inc. (Novartis), to develop and commercialize bispecific and other Fc engineered antibody drug candidates using the Company’s proprietary XmAb technologies and drug candidates. The Company received an upfront payment of $150.0 million and is eligible to receive additional development, regulatory and sales milestones. Pursuant to the Novartis Agreement: ● The Company granted Novartis certain exclusive rights to research, develop and commercialize XmAb14045 and XmAb13676, two development stage products that incorporate the Company’s bispecific Fc technology; ● The Company will apply its bispecific technology in up to four target pair antibodies identified by Novartis (each a Global Discovery Program); and ● The Company will provide Novartis with a non-exclusive license to certain of its Fc technologies to apply against up to ten targets identified by Novartis. The Company determined that the transaction price of the Novartis Agreement at inception was the $150.0 million upfront payment. The potential milestones were not included in the transaction price as these are contingent on future events, and the Company will not recognize these potential milestones in revenue until it is not probable that these would not result in significant reversal of revenue amounts in future periods. The Company will re-assess the transaction price at each reporting period and when event outcomes are resolved or changes in circumstances occur. Under the Novartis Agreement, the Company and Novartis are co-developing XmAb14045 worldwide and sharing development costs. In December 2018, Novartis notified us that they were returning their rights to the XmAb13676 program. Pursuant to the terms of the Novartis Agreement, the rights to the XmAb13676 program reverted to us in June 2019 and Novartis’ obligation to fund its share of XmAb13676 development costs will continue through June 2020. We completed delivery of a Global Discovery Program in 2017 and delivery of a second Global Discovery Program in 2018. Under the Novartis Agreement, Novartis will assume full responsibility for development and commercialization of each Global Discovery product candidate that is delivered. Assuming successful development and commercialization of a Global Discovery Program, we are eligible to receive $50.0 million in development milestones, $100.0 million in regulatory milestones and $100.0 million in sales milestones for each program. Pursuant to ASC 606, the potential milestone payments are considered variable consideration and were not included in determining the transaction price at inception of the Novartis Agreement. The Company has elected the most-likely-amount method for recognizing variable consideration. Under ASC 606, revenue is recognized at the time that the Company’s performance obligation for each Global Discovery is completed upon delivery of each discovery program to Novartis. In the third quarter ended September 30, 2019, Novartis notified the Company that the United States Food and Drug Administration (FDA) had allowed its Investigational New Drug application (IND) that was submitted for a Global Discovery bispecific antibody candidate, and Novartis intends to initiate a Phase 1 clinical trial for the candidate. Based on the expectation of a patient being dosed in the study, the Company recognized $10.0 million of revenue related to the expected Phase 1 milestone in the three-month period ended September 30, 2019. This amount was also recorded as a contract asset on the balance sheet at September 30, 2019. The Company recognized $10.0 million of revenue during the three and nine months ended September 30, 2019 in connection with the Novartis arrangement. The Company recognized $20.0 million of revenue in the three and nine months ended September 30, 2018. As of September 30, 2019 there is a receivable of $1.7 million related to cost-sharing of development activities for the third quarter of 2019 for the XmAb14045 and XmAb13676 programs, and $40.1 million in deferred revenue related to our obligation to deliver two additional Global Discovery Programs to Novartis under the arrangement. Amgen Inc. In September 2015, the Company entered into a research and license agreement (the Amgen Agreement) with Amgen Inc. (Amgen) to develop and commercialize bispecific antibody product candidates using the Company’s bispecific technology. Under the Amgen Agreement, the Company licensed the rights to its internally developed, preclinical CD38 x CD3 bispecific antibody candidate to Amgen and also agreed to apply our bispecific technology to five previously identified Amgen targets (each a Discovery Program). The Company has received a total of $55.0 million in upfront payments and milestone payments and is eligible to receive up to an additional $600.0 million in milestone payments and royalties on approved products. Pursuant to ASC 606, the milestone payments are considered variable consideration and were not included in determining the transaction price at inception of the Amgen Agreement. Pursuant to the Amgen Agreement, the Company applied its bispecific technology to five Discovery Programs antibody molecules provided by Amgen that bind Discovery Program targets and returned the bispecific product candidates to Amgen for further testing, development and commercialization. The initial research term was three years from the date of the Amgen Agreement, but Amgen, at its option, could request an extension of one year. In May 2018, Amgen elected to extend the term of the research term for one year. During the extended research term, the Company provided additional research activities to Amgen and received research funding for such activities. The extended research term expired in May 2019. In the third quarter ended September 30, 2019, Amgen notified the Company that the FDA had allowed the IND that was submitted for AMG 509, a STEAP1 x CD3 bispecific antibody developed under the Amgen Agreement. Amgen indicated that it intends to initiate a Phase 1 clinical trial for AMG 509. Based on the expectation of a patient being dosed in the study, we recognized We recognized $5.0 million of revenue under this arrangement during the three and nine months ended September 30 2019. No revenue was recognized under the arrangement during the same periods in 2018. As of September 30, 2019, there was no deferred revenue related to the arrangement. MorphoSys AG In June 2010, the Company entered into a Collaboration and License Agreement with MorphoSys AG (MorphoSys) for a worldwide license to the Company’s patents and know-how to research, develop and commercialize our drug candidate XmAb5574 (subsequently renamed MOR208 and tafasitamab) with the right to sublicense under certain conditions. Under the agreement, the Company agreed to collaborate with MorphoSys to develop and commercialize tafasitamab. If certain developmental, regulatory and sales milestones are achieved, the Company is eligible to receive future milestone payments and royalties. In June 2017, MorphoSys initiated a Phase 3 clinical trial under the arrangement for which the Company received a milestone payment of $12.5 million. The Company recognized the payment as revenue in the period that the milestone event occurred. There were no revenues recognized under this arrangement for the three and nine months ended September 30, 2019 and 2018. As of September 30, 2019, the Company has no deferred revenue related to this agreement. Alexion Pharmaceuticals, Inc. In January 2013, the Company entered into an option and license agreement with Alexion Pharmaceuticals, Inc. (Alexion). Under the terms of the agreement, the Company granted to Alexion an exclusive research license, with limited sublicensing rights, to make and use our Xtend technology to evaluate and advance compounds against six different target programs during a five-year research term under the agreement. Alexion exercised its option to take a commercial license for our technology against a target that was developed as ALXN1210 and is currently marketed as Ultomiris®. The Company is eligible to receive contractual milestones for certain regulatory and commercial achievements and is also entitled to receive royalties based on a percentage of net sales of Ultomiris sold by Alexion, its affiliates or its sub licensees, which percentage is in the low single digits. Alexion’s royalty obligations continue on a product-by-product and country-by-country basis until the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country. In the third quarter of 2018, Alexion completed certain regulatory submission filings for ALXN1210, and the Company received $9.0 million in milestone payments. In the fourth quarter of 2018, Alexion completed certain regulatory submission filings and also received FDA marketing approval, and the Company received $11.0 million in milestone payments. In the second quarter of 2019, Alexion received marketing authorization from Japan’s Ministry of Health, Labour and Welfare, and the Company received a $4.0 million milestone. In the third quarter of 2019, Alexion received marketing authorization from the European Commission, and the Company received a $4.0 million milestone. Under ASC 606, we recognize revenue for sales-based royalties upon the subsequent sale of the product. We began earning royalty revenue from the sale of Ultomiris in 2019. For the three and nine months ended September 30, 2019, we have estimated royalty revenue of $1.4 million and $2.5 million, respectively, related to sales of Ultomiris. We recognized $4.0 million and $8.0 million of milestone revenue under the arrangement for the three and nine months ended September 30, 2019. We also recognized $1.4 million and $2.5 million of royalty revenue under this arrangement for the three and nine months ended September 30, 2019. There was $9.0 million of revenue recognized under this arrangement for the three and nine months ended September 30, 2018. As of September 30, 2019, there is no deferred revenue related to this agreement. Boehringer Ingelheim International GmbH In 2007, the Company entered into a Research License and Collaboration Agreement with Boehringer Ingelheim International GmbH (BI). Under the agreement, the Company provided BI with a three-year research license to one of the Company’s technologies and commercial options. BI elected to exercise two commercial licenses from the compounds identified during the research term and one compound was in clinical development. In the third quarter of 2019, BI discontinued development of the compound and terminated the agreement. No revenue related to this arrangement was recognized for the three and nine months ended September 30, 2019 and 2018 and there is no deferred revenue related to this agreement at September 30, 2019. INmune Bio, Inc. In October 2017, the Company entered into a License Agreement with INmune Bio, Inc. (INmune). Under the terms of the agreement, the Company provided INmune with an exclusive license to certain rights to a proprietary protein, XPRO1595. Under the agreement the Company received an upfront payment of $100,000, an equity interest in INmune and an option to acquire additional shares of INmune. The Company is eligible to receive a percentage of sublicensing revenue received for XPRO1595 and also royalties in the mid-single digit percentages on the sale of approved products. The equity interest in INmune constituted of 1,585,000 shares of common stock and the option is to purchase up to an additional 10% of the fully diluted outstanding share of INmune for $10.0 million. We have recorded our equity interest in INmune at cost pursuant to ASC 323. We did not record our share of the net loss from INmune during the nine months ended September 30, 2019 or 2018, respectively, as the carrying value of this investment has been reduced to zero. In 2018, INmune filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) which was declared effective by the SEC as of December 19, 2018. The Company did not recognize any revenue related to the agreement for the three and nine months ended September 30, 2019 and 2018. There is no deferred revenue as of September 30, 2019 related to this agreement. VIR Biotechnology, Inc. In the third quarter of 2019, the Company entered into a Patent License Agreement (the VirBio Agreement) with VIR Biotechnology (VirBio) pursuant to which the Company provided a non-exclusive license to its Xtend technology for up to two targets. Under the terms of the VirBio Agreement, the Company received an upfront payment and is eligible to receive total milestones of $155.5 million which include $5.5 million of development milestones, $30.0 million of regulatory milestones and $120.0 million of sales milestones. In addition, the Company is eligible to receive royalties on the net sales of approved products in the low single digits. The Company evaluated the VirBio Agreement and determined that the single performance obligation was access to a non-exclusive license to certain patents of the Company which were transferred to VirBio upon execution of the VioBio Agreement in July 2019. The Company recognized $0.7 million of license and milestone revenue related to the agreement for the three and nine months ended September 30, 2019. There is no deferred revenue as of September 30, 2019 related to this agreement. Revenue earned The revenues recorded for the three and nine months ended September 30, 2019 were earned principally from the following licensees (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Alexion $ 5.4 $ 9.0 $ 10.5 $ 9.0 Amgen 5.0 — 5.0 — Astellas — — 13.8 — Genentech 0.7 — 113.2 — Novartis 10.0 20.0 10.0 20.0 Vir Biotechnology 0.7 — 0.7 — Total $ 21.8 $ 29.0 $ 153.2 $ 29.0 The table below summarizes the disaggregation of revenue recorded for the three and nine months ended September 30, 2019 (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Research collaboration $ 0.6 $ 20.0 $ 15.2 $ 20.0 Milestone 19.3 9.0 23.3 9.0 Licensing 0.5 — 112.2 — Royalties 1.4 — 2.5 — Total $ 21.8 $ 29.0 $ 153.2 $ 29.0 Remaining Performance Obligations and Deferred Revenue Our remaining performance obligations are delivery of two Global Discovery Programs under the Novartis Agreement and the conduct of research activities pursuant to research plans under the Genentech and Astellas Agreements. As of September 30, 2019 and 2018, we have deferred revenue of $48.2 million and $40.1 million, respectively. As of September 30, 2019, $45.6 million was classified as current liabilities as our obligations to perform services are due on demand when requested by Novartis and Astellas under the Novartis Agreement and Astellas Agreement, respectively; $2.6 million of the deferred revenue liability is classified as long-term for the obligation to perform research services to Genentech after one year. |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2019 | |
Income Taxes | |
Income Taxes | 11. Income taxes The provision for income taxes of $0.6 million for the nine months ended September 30, 2019 represents the interim period tax allocation of the state alternative minimum tax based on the Company’s projected year-end effective income tax rates which cannot be offset by the Company’s net operating loss carryforwards. The Company has a federal income tax receivable of $0.8 million at September 30, 2019 related to refundable alternative minimum tax credits. As of September 30, 2019, the Company’s deferred income tax assets, consisting primarily of net operating loss and tax credit carryforwards, have been fully offset by a valuation allowance. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Polices) | 9 Months Ended |
Sep. 30, 2019 | |
Summary of Significant Accounting Policies | |
Basis of Presentation | Basis of Presentation The accompanying unaudited interim financial statements for Xencor, Inc. (the Company, Xencor, we or us) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. Certain amounts in the prior period financial statements have been revised to conform to the presentation of the current period financial statements. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. The preparation of interim financial statements requires the use of management’s estimates and assumptions that affect reported amounts of assets and liabilities at the date of the interim financial statements and the reported revenues and expenditures during the reported periods. These interim financial results are not necessarily indicative of the results expected for the full fiscal year or for any subsequent interim period. The accompanying unaudited interim financial statements and related notes should be read in conjunction with the audited financial statements and notes thereto included in the Company’s 2018 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2019. |
Use of Estimates | Use of Estimates The preparation of interim financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, other comprehensive gain (loss) and the related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to its accrued clinical trial and manufacturing development expenses, stock-based compensation expense, intangible assets and related amortization. Significant estimates in these interim financial statements include estimates made for royalties and accrued research and development expenses, stock-based compensation expenses, intangible assets and related amortization, estimated standalone selling price of performance obligations, the likelihood of recognizing variable consideration, and recoverability of deferred tax assets. |
Intangible Assets | Intangible Assets The Company maintains definite-lived intangible assets related to certain capitalized costs of acquired licenses and third-party costs incurred in establishing and maintaining its intellectual property rights to its platform technologies and development candidates. These assets are amortized over their useful lives, which are estimated to be the remaining patent life or the contractual term of the license. The straight-line method is used to record amortization expense. The Company assesses its intangible assets for impairment if indicators are present or changes in circumstances suggest that impairment may exist. There were no impairment charges recorded for the nine months ended September 30, 2019 and 2018. The Company capitalizes certain in-process intangible assets that are abandoned when they are no longer pursued or used in current research activities. There was no material abandonment of in-process intangible assets during the nine months ended September 30, 2019 or 2018. |
Marketable Securities | Marketable Securities The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The Company invests its excess cash primarily in marketable debt securities issued by investment grade institutions. The Company considers its marketable debt securities to be available-for-sale. These assets are carried at fair value and the unrealized gains and losses are included in accumulated other comprehensive income (loss). Accrued interest on marketable debt securities is included in marketable securities. If a decline in the value of a marketable debt security in the Company’s investment portfolio is deemed to be other-than-temporary, the Company writes down the security to its current fair value and recognizes a loss as a charge against income. The Company reviews its portfolio of marketable debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost are other-than-temporary. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Pronouncements Adopted in 2019 Effective January 1, 2019, the Company adopted Accounting Standards Codification Topic 842 (ASC 842), Leases At inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases with a term of one year or longer where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit with such leases is typically not readily determined. The Company has determined the appropriate incremental borrowing rate by reference to an estimate of the current market borrowing rate for a collateralized asset over a similar term as the lease term. The new standard impacts our reporting on the leases on our facilities in Monrovia and San Diego. Under ASC 842, tenant allowances under such operating leases are no longer tracked separately as a deferred rent liability; instead, it is integrated as part of the ROU asset. As a result, we recorded an adjustment to the beginning balance for deferred rent liability and adopted the use of ROU asset and lease liability. We recorded lease liabilities of $12.7 million and ROU assets of $11.4 million for lease agreements in effect as of January 1, 2019. The ROU asset is included in Other assets on the balance sheet as of September 30, 2019. This resulted in an increase to the beginning balance on both assets and liabilities after the adjustment of $11.2 million, with no impact on our retained earnings. Effective January 1, 2019, the Company adopted ASU No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payments issued to nonemployees for goods and services. The standard requires a modified retrospective transition approach, with a cumulative adjustment to retained earnings as of adoption date, for all liability-classified awards that have not been settled as of the adoption date and equity-classified nonemployee awards for which a measurement date has not been established. The adoption of this standard did not have any impact on the Company’s financial statements. |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Fair Value of Financial Instruments | |
Schedule of assets recorded at fair value | September 30, 2019 December 31, 2018 Total Total Fair Value Level 1 Level 2 Fair Value Level 1 Level 2 Money Market Funds $ 30,603 $ 30,603 $ — $ 18,270 $ 18,270 $ — Corporate Securities 217,702 — 217,702 104,967 — 104,967 Government Securities 351,585 — 351,585 399,256 — 399,256 $ 599,890 $ 30,603 $ 569,287 $ 522,493 $ 18,270 $ 504,223 |
Net Income (Loss) Per Share (Ta
Net Income (Loss) Per Share (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Net Income (Loss) Per Share | |
Schedule of basic and diluted net income (loss) per common share | Basic and diluted net income (loss) per common share is computed as follows (in thousands except share and per share data): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 (in thousands, except share and per share data) Numerator: Net income (loss) attributable to common stockholders $ (10,224) $ 3,150 $ 53,787 $ (52,210) Denominator: Weighted-average common shares outstanding used in computing basic net income (loss) 56,643,075 55,974,080 56,449,678 53,165,774 Weighted-average common shares outstanding used in computing diluted net income (loss) 56,643,075 58,313,002 58,365,158 53,165,774 Basic net income (loss) per common share $ (0.18) $ 0.06 $ 0.95 $ (0.98) Diluted net income (loss) per common share $ (0.18) $ 0.05 $ 0.92 $ (0.98) |
Schedule of securities included in the calculation of earnings per share | Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 (in thousands) (in thousands) Employee stock purchase plan shares — — 20 — Options to purchase common stock and RSU grants — 2,339 1,895 — — 2,339 1,915 — |
Schedule of potentially dilutive securities | Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 (in thousands) (in thousands) Employee stock purchase plan shares 6 — — — Options to purchase common stock and RSU grants 2,261 — — 1,884 2,267 — — 1,884 |
Marketable Securities (Tables)
Marketable Securities (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Marketable Securities | |
Schedule of marketable securities | Gross Gross Amortized Unrealized Unrealized September 30, 2019 Cost Gains Losses Fair Value (in thousands) Money Market Funds $ 30,603 $ — $ — $ 30,603 Corporate Securities 217,484 228 (10) 217,702 Government Securities 350,358 1,227 — 351,585 $ 598,445 $ 1,455 $ (10) $ 599,890 Reported as Cash and cash equivalents $ 30,603 Marketable securities 569,287 Total investments $ 599,890 Gross Gross Amortized Unrealized Unrealized December 31, 2018 Cost Gains Losses Fair Value (in thousands) Money Market Funds $ 18,270 $ — $ — $ 18,270 Corporate Securities 105,311 1 (345) 104,967 Government Securities 399,873 187 (804) 399,256 $ 523,454 $ 188 $ (1,149) $ 522,493 Reported as Cash and cash equivalents $ 18,270 Marketable securities 504,223 Total investments $ 522,493 |
Schedule of maturities of marketable securities | Amortized Estimated September 30, 2019 Cost Fair Value (in thousands) Mature in one year or less $ 494,248 $ 495,292 Mature within two years 73,594 73,995 $ 567,842 $ 569,287 |
Schedule of unrealized losses on available-for-sale investments | The unrealized losses on available-for-sale investments and their related fair values as of September 30, 2019 and December 31, 2018 are as follows: Less than 12 months 12 months or greater Unrealized Unrealized September 30, 2019 Fair value losses Fair value losses (in thousands) Corporate Securities $ 3,037 $ (1) $ 21,409 $ (9) Government Securities 15,606 (1) — — $ 18,643 $ (2) $ 21,409 $ (9) Less than 12 months 12 months or greater Unrealized Unrealized December 31, 2018 Fair value losses Fair value losses (in thousands) Corporate Securities $ 84,666 $ (310) $ 17,805 $ (35) Government Securities 176,225 (672) 116,830 (132) $ 260,891 $ (982) $ 134,635 $ (167) |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Stock-Based Compensation | |
Schedule of total employee, director and non-employee stock-based compensation expense recognized | Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 General and administrative $ 2,474 $ 2,732 $ 6,337 $ 6,037 Research and development 7,040 3,388 18,336 9,436 $ 9,514 $ 6,120 $ 24,673 $ 15,473 Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Stock options $ 9,117 $ 5,832 $ 23,588 $ 14,723 ESPP 217 209 630 562 Restricted stock units 180 79 455 188 $ 9,514 $ 6,120 $ 24,673 $ 15,473 |
Summary of stock option activity | Weighted Weighted Average Average Number of Exercise Remaining Aggregate Shares subject Price Contractual Intrinsic to outstanding (Per Term Value options Share) (in years) (in thousands) Balances at December 31, 2018 5,966,928 $ 19.71 7.51 Options granted 1,918,375 $ 35.76 Options forfeited (266,780) $ 31.36 Options exercised (387,430) $ 17.95 Balances at September 30, 2019 7,231,093 $ 23.63 7.47 $ 78,789 Exercisable 3,831,677 $ 17.25 6.28 $ 63,736 |
Schedule of weighted average assumptions used for estimation of fair value of stock options | Options Options Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (years) 6.0 6.1 6.0 6.1 Expected volatility 60.8 % 72.8 % 61.2 % 73.1 % Risk-free interest rate 1.52 % 2.87 % 2.33 % 2.56 % Expected dividend yield — % — % — % — % |
Schedule of weighted average assumptions used for estimation of fair value of ESPP | ESPP ESPP Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (years) 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 Expected volatility 55.0 - 71.4 % 61.2 - 71.4 % 55.0 - 71.4 % 61.2 - 71.4 % Risk-free interest rate 1.47 - 2.70 % 1.47 - 2.41 % 1.47 - 2.70 % 1.47 - 2.41 % Expected dividend yield — % — % — % — % |
Summary of restricted stock unity activity | Weighted Restricted Average Grant Stock Date Fair Value Units (Per unit) Unvested at December 31, 2018 33,933 $ 27.64 Granted 39,666 35.94 Vested (11,311) 27.64 Forfeited (4,182) 31.12 Unvested at September 30, 2019 58,106 $ 33.05 |
Leases (Tables)
Leases (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Leases | |
Schedule of operating lease liabilities maturities | The following table reconciles the undiscounted cash flows for the operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet (in thousands): Years ending December 31, For the remainder of 2019 $ 698 2020 2,703 2021 2,587 2022 2,208 2023 1,352 2024 1,371 Thereafter 2,282 Total undiscounted lease payments 13,201 Less: Imputed interest (1,922) Present value of lease payments $ 11,279 Lease liabilities - short-term $ 2,197 Lease liabilities - long-term 9,082 Total lease liabilities $ 11,279 |
Collaboration and Licensing A_2
Collaboration and Licensing Agreements (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Collaboration and Licensing Agreements | |
Schedule of revenue by licensees | The revenues recorded for the three and nine months ended September 30, 2019 were earned principally from the following licensees (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Alexion $ 5.4 $ 9.0 $ 10.5 $ 9.0 Amgen 5.0 — 5.0 — Astellas — — 13.8 — Genentech 0.7 — 113.2 — Novartis 10.0 20.0 10.0 20.0 Vir Biotechnology 0.7 — 0.7 — Total $ 21.8 $ 29.0 $ 153.2 $ 29.0 |
Schedule of disaggregation of revenue | The table below summarizes the disaggregation of revenue recorded for the three and nine months ended September 30, 2019 (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Research collaboration $ 0.6 $ 20.0 $ 15.2 $ 20.0 Milestone 19.3 9.0 23.3 9.0 Licensing 0.5 — 112.2 — Royalties 1.4 — 2.5 — Total $ 21.8 $ 29.0 $ 153.2 $ 29.0 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies - Intangibles (Details) - USD ($) | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Summary of Significant Accounting Policies | ||
Impairment of intangible assets | $ 0 | $ 0 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($) | Sep. 30, 2019 | Jan. 01, 2019 | Dec. 31, 2018 |
Lease liability | $ 11,279,000 | ||
Increase in assets | 686,244,000 | $ 576,732,000 | |
Increase in liabilities | 76,007,000 | 55,051,000 | |
Impact on retained earnings (accumulated deficit) | $ (269,490,000) | $ (323,277,000) | |
ASU 2016-02 | Restatement Adjustment | |||
Right-of-Use Asset | $ 11,400,000 | ||
Lease liability | 12,700,000 | ||
Increase in assets | 11,200,000 | ||
Increase in liabilities | 11,200,000 | ||
Impact on retained earnings (accumulated deficit) | $ 0 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 | Sep. 30, 2018 |
Fair Value of Financial Instruments | |||
Money Market Funds | $ 51,189 | $ 26,246 | |
Securities | 569,287 | ||
Total Fair Value | 599,890 | 522,493 | |
Transfers from level 1 to level 2 | 0 | $ 0 | |
Transfers from level 2 to level 1 | 0 | $ 0 | |
Money Market Funds | |||
Fair Value of Financial Instruments | |||
Money Market Funds | 30,603 | 18,270 | |
Corporate Securities | |||
Fair Value of Financial Instruments | |||
Securities | 217,702 | 104,967 | |
Government Securities | |||
Fair Value of Financial Instruments | |||
Securities | 351,585 | 399,256 | |
Level 1 | |||
Fair Value of Financial Instruments | |||
Total Fair Value | 30,603 | 18,270 | |
Level 1 | Money Market Funds | |||
Fair Value of Financial Instruments | |||
Money Market Funds | 30,603 | 18,270 | |
Level 2 | |||
Fair Value of Financial Instruments | |||
Total Fair Value | 569,287 | 504,223 | |
Level 2 | Corporate Securities | |||
Fair Value of Financial Instruments | |||
Securities | 217,702 | 104,967 | |
Level 2 | Government Securities | |||
Fair Value of Financial Instruments | |||
Securities | $ 351,585 | $ 399,256 |
Net Income (Loss) Per Share (De
Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Numerator: | ||||
Net income (loss) attributable to common stockholders | $ (10,224) | $ 3,150 | $ 53,787 | $ (52,210) |
Denominator: | ||||
Weighted average common shares outstanding, basic | 56,643,075 | 55,974,080 | 56,449,678 | 53,165,774 |
Weighted average common shares outstanding, diluted | 56,643,075 | 58,313,002 | 58,365,158 | 53,165,774 |
Basic net income (loss) per common share | $ (0.18) | $ 0.06 | $ 0.95 | $ (0.98) |
Diluted net income (loss) per common share | $ (0.18) | $ 0.05 | $ 0.92 | $ (0.98) |
Net Income (Loss) Per Share - S
Net Income (Loss) Per Share - Securities included in EPS calculation (Details) - shares shares in Thousands | 3 Months Ended | 9 Months Ended |
Sep. 30, 2018 | Sep. 30, 2019 | |
Net Income (Loss) Per Share | ||
Securities included in calculation of EPS | 2,339 | 1,915 |
ESPP | ||
Net Income (Loss) Per Share | ||
Securities included in calculation of EPS | 20 | |
Options to purchase common stock and RSU grants | ||
Net Income (Loss) Per Share | ||
Securities included in calculation of EPS | 2,339 | 1,895 |
Net Income (Loss) Per Share - A
Net Income (Loss) Per Share - Anti-dilutive securities (Details) - shares shares in Thousands | 3 Months Ended | 9 Months Ended |
Sep. 30, 2019 | Sep. 30, 2018 | |
Net Income (Loss) Per Share | ||
Anti-dilutive securities (in shares) | 2,267 | 1,884 |
ESPP | ||
Net Income (Loss) Per Share | ||
Anti-dilutive securities (in shares) | 6 | |
Options to purchase common stock and RSU grants | ||
Net Income (Loss) Per Share | ||
Anti-dilutive securities (in shares) | 2,261 | 1,884 |
Marketable Securities (Details)
Marketable Securities (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 |
Schedule of Available-for-sale Securities | ||
Cash and cash equivalents | $ 51,189 | $ 26,246 |
Investments, amortized cost | 598,445 | 523,454 |
Investments | 599,890 | 522,493 |
Total amortized cost | 567,842 | |
Gross unrealized gains | 1,455 | 188 |
Gross unrealized losses | (10) | (1,149) |
Securities | 569,287 | |
Marketable securities | ||
Schedule of Available-for-sale Securities | ||
Securities | 569,287 | 504,223 |
Money Market Funds | ||
Schedule of Available-for-sale Securities | ||
Cash and cash equivalents | 30,603 | 18,270 |
Corporate Securities | ||
Schedule of Available-for-sale Securities | ||
Total amortized cost | 217,484 | 105,311 |
Gross unrealized gains | 228 | 1 |
Gross unrealized losses | (10) | (345) |
Securities | 217,702 | 104,967 |
Government Securities | ||
Schedule of Available-for-sale Securities | ||
Total amortized cost | 350,358 | 399,873 |
Gross unrealized gains | 1,227 | 187 |
Gross unrealized losses | (804) | |
Securities | 351,585 | 399,256 |
Cash and Cash Equivalents | ||
Schedule of Available-for-sale Securities | ||
Cash and cash equivalents | $ 30,603 | $ 18,270 |
Marketable Securities - Maturit
Marketable Securities - Maturities (Details) $ in Thousands | Sep. 30, 2019USD ($) |
Amortized Cost | |
Maturing in one year or less | $ 494,248 |
Maturing within two years | 73,594 |
Total amortized cost | 567,842 |
Estimate Fair Value | |
Maturing in one year or less | 495,292 |
Maturing within two years | 73,995 |
Total estimated fair value | $ 569,287 |
Marketable Securities - Unreali
Marketable Securities - Unrealized losses (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 |
Fair value | ||
Fair value, less than 12 months | $ 18,643 | $ 260,891 |
Fair value, 12 months or greater | 21,409 | 134,635 |
Unrealized losses | ||
Unrealized losses, Less than 12 months | (2) | (982) |
Unrealized losses, 12 months or greater | (9) | (167) |
Corporate Securities | ||
Fair value | ||
Fair value, less than 12 months | 3,037 | 84,666 |
Fair value, 12 months or greater | 21,409 | 17,805 |
Unrealized losses | ||
Unrealized losses, Less than 12 months | (1) | (310) |
Unrealized losses, 12 months or greater | (9) | (35) |
Government Securities | ||
Fair value | ||
Fair value, less than 12 months | 15,606 | 176,225 |
Fair value, 12 months or greater | 116,830 | |
Unrealized losses | ||
Unrealized losses, Less than 12 months | $ (1) | (672) |
Unrealized losses, 12 months or greater | $ (132) |
Sale of Additional Common Sto_2
Sale of Additional Common Stock (Details) - Common Stock - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended |
Mar. 31, 2018 | Mar. 31, 2018 | |
Sale of common stock | 8,395,000 | 8,395,000 |
Net proceeds | $ 245.5 |
Stock Based Compensation (Detai
Stock Based Compensation (Details) | Dec. 02, 2013shares | Sep. 30, 2019itemshares | Sep. 30, 2018shares | Dec. 31, 2018shares |
Stock-based compensation | ||||
Common stock, shares issued | 56,714,788 | 56,279,542 | ||
Employee stock options | ||||
Stock-based compensation | ||||
Options granted (in shares) | 1,918,375 | 1,679,400 | ||
ESPP | ||||
Stock-based compensation | ||||
Total number of shares of common stock available for issuance | 581,286 | |||
Awards issued under the plan (in shares) | 386,221 | |||
Increase in shares of common stock available for issuance (in shares) | 0 | |||
ESPP | Maximum | ||||
Stock-based compensation | ||||
Annual percentage increase in shares of common stock available for issuance | 1.00% | |||
Annual increase in shares of common stock available for issuance (in shares) | 621,814 | |||
Restricted stock units | ||||
Stock-based compensation | ||||
Awards issued under the plan (in shares) | 73,599 | |||
Annual installment vesting periods | item | 3 | |||
The 2013 Plan | ||||
Stock-based compensation | ||||
Total number of shares of common stock available for issuance | 11,434,273 | |||
Annual percentage increase in shares of common stock available for issuance | 4.00% | |||
Awards issued under the plan (in shares) | 8,669,662 | |||
Increase in shares of common stock available for issuance (in shares) | 2,251,181 | |||
The 2010 Plan | ||||
Stock-based compensation | ||||
Total number of shares of common stock available for issuance | 2,684,456 | |||
Options granted (in shares) | 0 |
Stock-Based Compensation - Empl
Stock-Based Compensation - Employee expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Stock-based compensation | ||||
Total employee, director and non-employee stock-based compensation expense | $ 9,514 | $ 6,120 | $ 24,673 | $ 15,473 |
Employee stock options | ||||
Stock-based compensation | ||||
Total employee, director and non-employee stock-based compensation expense | 9,117 | 5,832 | 23,588 | 14,723 |
ESPP | ||||
Stock-based compensation | ||||
Total employee, director and non-employee stock-based compensation expense | 217 | 209 | 630 | 562 |
Restricted stock units | ||||
Stock-based compensation | ||||
Total employee, director and non-employee stock-based compensation expense | 180 | 79 | 455 | 188 |
General and administrative | ||||
Stock-based compensation | ||||
Total employee, director and non-employee stock-based compensation expense | 2,474 | 2,732 | 6,337 | 6,037 |
Research and development | ||||
Stock-based compensation | ||||
Total employee, director and non-employee stock-based compensation expense | $ 7,040 | $ 3,388 | $ 18,336 | $ 9,436 |
Stock-Based Compensation - Opti
Stock-Based Compensation - Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | Dec. 02, 2013 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 |
Employee stock options | ||||
Number of Shares subject to outstanding options | ||||
Balance at the beginning of the period (in shares) | 5,966,928 | |||
Options granted (in shares) | 1,918,375 | 1,679,400 | ||
Options forfeited (in shares) | (266,780) | |||
Options exercised (in shares) | (387,430) | |||
Balance at the end of the period (in shares) | 7,231,093 | 5,966,928 | ||
Exercisable options (in shares) | 3,831,677 | |||
Weighted Average Exercise Price (Per Share) | ||||
Balance at the beginning of the period (in dollars per share) | $ 19.71 | |||
Options granted (in dollars per share) | 35.76 | |||
Options forfeited (in dollars per share) | 31.36 | |||
Options exercised (in dollars per share) | 17.95 | |||
Balance at the end of the period (in dollars per share) | 23.63 | $ 19.71 | ||
Exercisable (in dollars per share) | $ 17.25 | |||
Weighted-average remaining contractual life | 7 years 5 months 19 days | 7 years 6 months 3 days | ||
Weighted-average remaining contractual life of awards exercisable | 6 years 3 months 10 days | |||
Aggregate intrinsic value of options outstanding | $ 78,789 | |||
Aggregate intrinsic value of options exercisable | $ 63,736 | |||
Closing price of common stock (in dollars per share) | $ 33.73 | |||
Weighted average fair value of options granted (in dollars per share) | $ 20.71 | $ 17.57 | ||
The 2010 Plan | ||||
Number of Shares subject to outstanding options | ||||
Options granted (in shares) | 0 |
Stock-Based Compensation - FV o
Stock-Based Compensation - FV of employee stock options (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Employee stock options | ||||
Weighted average assumptions for estimated fair value of employee stock options | ||||
Expected volatility (as a percent) | 60.80% | 72.80% | 61.20% | 73.10% |
Risk-free interest rate (as a percent) | 1.52% | 2.87% | 2.33% | 2.56% |
Expected term (years) | 6 years | 6 years 1 month 6 days | 6 years | 6 years 1 month 6 days |
Compensation expense | ||||
Unamortized compensation expense related to unvested options | $ 56.6 | $ 56.6 | ||
Period to recognize unamortized compensation expense | 2 years 5 months 12 days | |||
ESPP | ||||
Weighted average assumptions for estimated fair value of employee stock options | ||||
Expected volatility, low end of range (as a percent) | 55.00% | 61.20% | 55.00% | 61.20% |
Expected volatility, high end of range (as a percent) | 71.40% | 71.40% | 71.40% | 71.40% |
Risk-free interest rate, low end of range (as a percent) | 1.47% | 1.47% | 1.47% | 1.47% |
Risk-free interest rate, high end of range (as a percent) | 2.70% | 2.41% | 2.70% | 2.41% |
Compensation expense | ||||
Unamortized compensation expense related to unvested options | $ 0.1 | $ 0.1 | ||
Period to recognize unamortized compensation expense | 2 months 12 days | |||
ESPP | Minimum | ||||
Weighted average assumptions for estimated fair value of employee stock options | ||||
Expected term (years) | 6 months | 6 months | 6 months | 6 months |
ESPP | Maximum | ||||
Weighted average assumptions for estimated fair value of employee stock options | ||||
Expected term (years) | 2 years | 2 years | 2 years | 2 years |
Stock Based Compensation - Rest
Stock Based Compensation - Restricted stock units (Details) - Restricted stock units $ / shares in Units, $ in Thousands | 9 Months Ended |
Sep. 30, 2019USD ($)$ / sharesshares | |
Stock-based compensation | |
Beginning balance | shares | 33,933 |
Granted | shares | 39,666 |
Vested | shares | (11,311) |
Forfeited | shares | (4,182) |
Ending balance | shares | 58,106 |
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares | $ 27.64 |
Weighted Average Grant Date Fair Value, Granted | $ / shares | 35.94 |
Weighted Average Grant Date Fair Value, Vested | $ / shares | 27.64 |
Weighted Average Grant Date Fair Value, Forfeited | $ / shares | 31.12 |
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares | $ 33.05 |
Compensation expense | |
Unamortized compensation expense related to unvested restricted stock units | $ | $ 1,500 |
Period to recognize unamortized compensation expense | 2 years 2 months 12 days |
Leases (Details)
Leases (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2019 | Jul. 31, 2017 | |
Lessee, Lease, Description [Line Items] | ||
Option to extend | true | |
For the remainder of 2019 | $ 698 | |
2020 | 2,703 | |
2021 | 2,587 | |
2022 | 2,208 | |
2023 | 1,352 | |
2024 | 1,371 | |
Thereafter | 2,282 | |
Total undiscounted lease payments | 13,201 | |
Less: Imputed interest | (1,922) | |
Present value of lease payments | $ 11,279 | |
Monrovia, CA - office and laboratory space | ||
Lessee, Lease, Description [Line Items] | ||
Renewal term | 5 years | |
Monrovia, CA - office and laboratory space with additional space | ||
Lessee, Lease, Description [Line Items] | ||
Renewal term | 5 years | |
San Diego, CA - office space | ||
Lessee, Lease, Description [Line Items] | ||
Renewal term | 5 years | |
San Diego, CA - second office space | ||
Lessee, Lease, Description [Line Items] | ||
Renewal term | 5 years |
Leases - Operating lease liabil
Leases - Operating lease liabilities (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Leases | ||
Lease liability - short-term | $ 2,197 | |
Lease liability - long-term | 9,082 | |
Operating lease liabilities | 11,279 | |
Operating lease cost | 2,000 | |
Cash paid for operating leases | $ 1,900 | |
Net rent expense | $ 1,900 | |
Remaining lease term | 5 years 8 months 12 days | |
Discount rate | 5.50% |
Collaboration and Licensing A_3
Collaboration and Licensing Agreements (Details) | Mar. 29, 2019USD ($) | Jun. 30, 2019USD ($) | Mar. 31, 2019USD ($) | Feb. 28, 2019USD ($)companyitem | Oct. 31, 2017USD ($)shares | Jun. 30, 2017USD ($) | Jun. 30, 2016USD ($)item | Sep. 30, 2015USD ($)item | Jan. 31, 2013item | Sep. 30, 2019USD ($)item | Jun. 30, 2019USD ($) | Dec. 31, 2018USD ($) | Sep. 30, 2018USD ($) | Sep. 30, 2019USD ($)item | Sep. 30, 2018USD ($) | Dec. 31, 2007item |
Collaboration research and licensing agreements | ||||||||||||||||
Deferred revenue | $ 48,200,000 | $ 40,100,000 | $ 48,200,000 | $ 40,100,000 | ||||||||||||
Current portion of deferred revenue | 45,579,000 | $ 40,079,000 | 45,579,000 | |||||||||||||
Deferred revenue, noncurrent portion | 2,613,000 | $ 2,613,000 | ||||||||||||||
Novartis | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Number of performance obligations | 2 | |||||||||||||||
Collaboration and License Agreement | Genentech | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Nonrefundable upfront payment | $ 120,000,000 | |||||||||||||||
Percentage of profits on net sales of the product | 45.00% | |||||||||||||||
Research license term | 2 years | |||||||||||||||
Revenue recognized | 700,000 | $ 113,200,000 | ||||||||||||||
Number of companies that conduct integrated research plan | company | 2 | |||||||||||||||
Performance obligation | $ 120,000,000 | |||||||||||||||
Number of programs | item | 9 | |||||||||||||||
Term of revenue recognized | 1 year | |||||||||||||||
Collaboration and License Agreement | Genentech | XmAb24306 | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Performance obligation | $ 111,700,000 | |||||||||||||||
Cost sharing receivable (payable) | (500,000) | $ (500,000) | ||||||||||||||
Collaboration and License Agreement | Genentech | Research service | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Revenue recognized | 1,600,000 | |||||||||||||||
Performance obligation | 8,300,000 | |||||||||||||||
Deferred revenue | 6,800,000 | 6,800,000 | ||||||||||||||
Collaboration and License Agreement | Genentech | Licensing | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Revenue recognized | $ 111,700,000 | |||||||||||||||
Collaboration and License Agreement | Genentech | Maximum | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Potential milestone payment | 160,000,000 | |||||||||||||||
Collaboration and License Agreement | Genentech | Market assessment approach | Licensing | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Standalone selling price | 114,400,000 | |||||||||||||||
Collaboration and License Agreement | Genentech | Cost approach | Research service | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Standalone selling price | 8,500,000 | |||||||||||||||
Collaboration and License Agreement | Genentech | Collaboration Products | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Performance obligation | 0 | 0 | ||||||||||||||
Collaboration and License Agreement | Novartis | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Nonrefundable upfront payment | $ 150,000,000 | |||||||||||||||
Revenue recognized | 20,000,000 | 10,000,000 | 20,000,000 | |||||||||||||
Performance obligation | $ 150,000,000 | |||||||||||||||
Deferred revenue | 40,100,000 | 40,100,000 | ||||||||||||||
Cost sharing receivable (payable) | 1,700,000 | $ 1,700,000 | ||||||||||||||
Collaboration and License Agreement | Novartis | Milestone | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Revenue recognized | 10,000,000 | |||||||||||||||
Collaboration and License Agreement | Novartis | Discovery Program | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Number of performance obligations | item | 2 | |||||||||||||||
Collaboration and License Agreement | Novartis | Bispecific FC Technologies | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Number of development stage products | item | 2 | |||||||||||||||
Collaboration and License Agreement | Novartis | Bispecific FC Technologies | Maximum | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Number of antibody targets for which bispecific technology applied | item | 4 | |||||||||||||||
Collaboration and License Agreement | Novartis | FC Licenses | Maximum | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Number of targets against which non-exclusive license is provided | item | 10 | |||||||||||||||
Collaboration and License Agreement | MorphoSys | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Revenue recognized | 0 | 0 | $ 0 | 0 | ||||||||||||
Deferred revenue | 0 | 0 | ||||||||||||||
Collaboration and License Agreement | MorphoSys | Milestone | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Revenue recognized | $ 12,500,000 | |||||||||||||||
Research and License Agreement | Astellas | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Nonrefundable upfront payment | $ 15,000,000 | |||||||||||||||
Potential milestone payment | 240,000,000 | |||||||||||||||
Revenue recognized | 0 | 13,800,000 | ||||||||||||||
Performance obligation | 15,000,000 | |||||||||||||||
Deferred revenue | 1,200,000 | 1,200,000 | ||||||||||||||
Research and License Agreement | Astellas | Bispecific | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Revenue recognized | $ 13,600,000 | |||||||||||||||
Performance obligation | 13,600,000 | |||||||||||||||
Research and License Agreement | Astellas | Research service | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Performance obligation | 1,400,000 | |||||||||||||||
Research and License Agreement | Astellas | Income approach | Bispecific | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Standalone selling price | 17,100,000 | |||||||||||||||
Research and License Agreement | Astellas | Cost approach | Research service | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Standalone selling price | 1,400,000 | |||||||||||||||
Research and License Agreement | Amgen, Inc. | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Upfront and milestone payment | $ 55,000,000 | |||||||||||||||
Potential milestone payment | $ 600,000,000 | |||||||||||||||
Revenue recognized | 5,000,000 | 0 | 5,000,000 | 0 | ||||||||||||
Deferred revenue | 0 | 0 | ||||||||||||||
Number of previously identified products | item | 5 | |||||||||||||||
Research and License Agreement | Amgen, Inc. | Milestone | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Revenue recognized | 5,000,000 | |||||||||||||||
Research and License Agreement | Amgen, Inc. | Discovery Program | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Research license term | 3 years | |||||||||||||||
Additional research term | 1 year | |||||||||||||||
Number of programs | item | 5 | |||||||||||||||
Research and License Agreement | VIR Biotechnology | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Potential milestone payment | 155,500,000 | 155,500,000 | ||||||||||||||
Revenue recognized | 700,000 | 700,000 | ||||||||||||||
Deferred revenue | $ 0 | 0 | ||||||||||||||
Number of different target programs | item | 2 | |||||||||||||||
Research Licensee and Collaboration Agreement | Boehringer Ingelheim International GmbH | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Research license term | 3 years | |||||||||||||||
Revenue recognized | $ 0 | 0 | 0 | 0 | ||||||||||||
Deferred revenue | 0 | $ 0 | ||||||||||||||
Number of commercial options | item | 1 | |||||||||||||||
Number of compounds | item | 1 | |||||||||||||||
Number of commercial licenses | item | 2 | |||||||||||||||
Option and license agreement | Alexion Pharmaceuticals, Inc. | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Research license term | 5 years | |||||||||||||||
Revenue recognized | $ 11,000,000 | 9,000,000 | 9,000,000 | |||||||||||||
Deferred revenue | 0 | $ 0 | ||||||||||||||
Number of different target programs | item | 6 | |||||||||||||||
Option and license agreement | Alexion Pharmaceuticals, Inc. | Royalty | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Revenue recognized | 1,400,000 | 2,500,000 | ||||||||||||||
Option and license agreement | Alexion Pharmaceuticals, Inc. | Milestone | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Revenue recognized | 4,000,000 | $ 4,000,000 | 9,000,000 | 8,000,000 | ||||||||||||
License Agreement | INmune | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Nonrefundable upfront payment | $ 100,000 | |||||||||||||||
Revenue recognized | 0 | 0 | 0 | 0 | ||||||||||||
Deferred revenue | 0 | 0 | ||||||||||||||
Additional equity interests (as a percentage) | 10.00% | |||||||||||||||
Equity issued in shares | shares | 1,585,000 | |||||||||||||||
Equity issues, value | $ 10,000,000 | |||||||||||||||
Carrying value | 0 | $ 0 | 0 | $ 0 | ||||||||||||
Development-based | Collaboration and License Agreement | Genentech | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Potential milestone payment | $ 20,000,000 | |||||||||||||||
Development-based | Collaboration and License Agreement | Novartis | Discovery Program | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Potential milestone payment | 50,000,000 | 50,000,000 | ||||||||||||||
Development-based | Research and License Agreement | Astellas | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Potential milestone payment | 32,500,000 | |||||||||||||||
Development-based | Research and License Agreement | VIR Biotechnology | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Potential milestone payment | 5,500,000 | 5,500,000 | ||||||||||||||
Regulatory-based | Collaboration and License Agreement | Novartis | Discovery Program | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Potential milestone payment | 100,000,000 | 100,000,000 | ||||||||||||||
Regulatory-based | Research and License Agreement | Astellas | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Potential milestone payment | 57,500,000 | |||||||||||||||
Regulatory-based | Research and License Agreement | VIR Biotechnology | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Potential milestone payment | 30,000,000 | 30,000,000 | ||||||||||||||
Sales-based | Collaboration and License Agreement | Novartis | Discovery Program | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Potential milestone payment | 100,000,000 | 100,000,000 | ||||||||||||||
Sales-based | Research and License Agreement | Astellas | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Potential milestone payment | $ 150,000,000 | |||||||||||||||
Sales-based | Research and License Agreement | VIR Biotechnology | ||||||||||||||||
Collaboration research and licensing agreements | ||||||||||||||||
Potential milestone payment | $ 120,000,000 | $ 120,000,000 |
Collaborative and Licensing Agr
Collaborative and Licensing Agreements - Revenue Recognition (Details) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Revenue recorded | $ 21,760,000 | $ 29,039,000 | $ 153,184,000 | $ 29,039,000 | |
Deferred revenue | 48,200,000 | 40,100,000 | 48,200,000 | 40,100,000 | |
Current portion of deferred revenue | 45,579,000 | 45,579,000 | $ 40,079,000 | ||
Deferred revenue, noncurrent portion | 2,613,000 | 2,613,000 | |||
Research collaboration | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Revenue recorded | 600,000 | 20,000,000 | 15,200,000 | 20,000,000 | |
Milestone | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Revenue recorded | 19,300,000 | 9,000,000 | 23,300,000 | 9,000,000 | |
Licensing | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Revenue recorded | 500,000 | 112,200,000 | |||
Royalty | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Revenue recorded | 1,400,000 | 2,500,000 | |||
Alexion Pharmaceuticals, Inc. | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Revenue recorded | 5,400,000 | 9,000,000 | 10,500,000 | 9,000,000 | |
Amgen, Inc. | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Revenue recorded | 5,000,000 | 5,000,000 | |||
Astellas | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Revenue recorded | 13,800,000 | ||||
Genentech | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Revenue recorded | 700,000 | $ 113,200,000 | |||
Novartis | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Number of performance obligations | 2 | ||||
Revenue recorded | 10,000,000 | $ 20,000,000 | $ 10,000,000 | $ 20,000,000 | |
VIR Biotechnology | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Revenue recorded | 700,000 | $ 700,000 | |||
Collaboration and License Agreement | Genentech | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Term of revenue recognized | 1 year | ||||
Collaboration and License Agreement | Novartis | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Deferred revenue | $ 40,100,000 | $ 40,100,000 |
Income Taxes (Details)
Income Taxes (Details) $ in Thousands | 3 Months Ended | 9 Months Ended |
Sep. 30, 2019USD ($) | Sep. 30, 2019USD ($) | |
Reconciliation of federal statutory income tax to effective income tax | ||
Income tax expense (benefit) | $ (350) | $ 600 |
Federal | ||
Reconciliation of federal statutory income tax to effective income tax | ||
Income tax receivable | $ 800 | $ 800 |